Lexeo Therapeutics (LXEO) CEO logs RSU grant and tax-driven share sale

Rhea-AI Filing Summary

Lexeo Therapeutics, Inc. Chief Executive Officer Richard Nolan Townsend reported two equity transactions involving the company’s common stock. He received a grant of 67,000 shares of common stock on June 29, 2026 at no cost as a compensation-related award. On July 1, 2026, he sold 25,947 shares at a weighted average price of $4.48 per share, with prices ranging from $4.3402 to $4.7507, specifically to cover tax obligations tied to the release of performance restricted stock units. After the sale, he directly owned 377,817 shares of common stock, which includes 252,130 restricted stock units, indicating he retains a substantial equity position in the company.

Insights

Equity compensation analyst

CEO reports routine RSU grant and tax-related share sale, retaining a large equity stake.

The CEO of Lexeo Therapeutics received a grant of 67,000 shares of common stock as compensation, then sold 25,947 shares at a weighted average of $4.48 per share. The filing states the sale was solely to cover tax obligations from performance RSU releases.

Following these transactions, he directly holds 377,817 shares, including 252,130 RSUs, so the net effect is an increased and still substantial position. Because the sale is tax-driven rather than discretionary portfolio rebalancing, and the CEO’s remaining stake is large, this appears to be a routine compensation event rather than a directional signal. Overall, it does not materially change the investment thesis.

Insider Trade Summary

Net Seller: 25,947 shares ($116,243)

Net Sell 2 txns

Insider Townsend Richard Nolan

Role Chief Executive Officer

Sold 25,947 shs ($116K)

Type	Security	Shares	Price	Value
Sale	Common Stock	25,947	$4.48	$116K
Grant/Award	Common Stock	67,000	$0.00	--

Holdings After Transaction: Common Stock — 377,817 shares (Direct, null)

Footnotes (1)

1. Represents a sale to cover tax obligations on the release of performance Restricted Stock Units ("RSUs"). This transaction was executed in multiple trades at prices ranging from $4.3402 to $4.7507. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Includes 252,130 RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.

Key Figures

Shares sold: 25,947 shares Sale price: $4.48 per share Shares granted: 67,000 shares +2 more

5 metrics

Shares sold 25,947 shares Open-market sale on July 1, 2026

Sale price $4.48 per share Weighted average; range $4.3402–$4.7507

Shares granted 67,000 shares Common stock award on June 29, 2026

Post-sale holdings 377,817 shares Direct ownership after July 1, 2026 sale

RSUs outstanding 252,130 RSUs Each RSU equals one common share

Key Terms

Restricted Stock Units (RSUs), weighted average sale price, contingent right, grant, award, or other acquisition

4 terms

Restricted Stock Units (RSUs) financial

"Represents a sale to cover tax obligations on the release of performance Restricted Stock Units ("RSUs")."

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

contingent right financial

"Each RSU represents a contingent right to receive one share of Common Stock of the Issuer."

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/01/2026 - 06:47 PM Accepted by SEC EDGAR 07/01/2026 - 06:47 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Townsend Richard Nolan

(Last) (First) (Middle)

C/O LEXEO THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, FLOOR 6

(Street)

NEW YORK NEW YORK 10010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/29/2026		A		67,000	A	$0	403,764	D
Common Stock	07/01/2026		S(1)		25,947	D	$4.48(2)	377,817(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a sale to cover tax obligations on the release of performance Restricted Stock Units ("RSUs").

2. This transaction was executed in multiple trades at prices ranging from $4.3402 to $4.7507. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. Includes 252,130 RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.

	/s/ Youjin Choi, Attorney-in-Fact	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Lexeo Therapeutics (LXEO) report for its CEO?

Lexeo Therapeutics’ CEO reported a grant of 67,000 common shares and a sale of 25,947 shares. The grant was a compensation award, while the sale covered tax obligations related to performance RSU releases, reflecting routine equity compensation activity rather than a strategic ownership shift.

How many Lexeo Therapeutics (LXEO) shares did the CEO sell and at what price?

The CEO sold 25,947 shares of Lexeo Therapeutics common stock at a weighted average price of $4.48. Individual trades occurred between $4.3402 and $4.7507, with the filing stating the transactions were executed in multiple trades and the average price is reported.

Why did the Lexeo Therapeutics (LXEO) CEO sell 25,947 shares of common stock?

The filing states the 25,947-share sale was to cover tax obligations arising from the release of performance RSUs. This indicates the disposition was tax-related rather than a discretionary reduction of his equity exposure, a common pattern with restricted stock unit vesting.

How many Lexeo Therapeutics (LXEO) shares does the CEO hold after these transactions?

After the reported grant and sale, the CEO directly holds 377,817 shares of Lexeo Therapeutics common stock. This total includes 252,130 restricted stock units, each representing a contingent right to receive one share, highlighting a significant ongoing equity interest in the company.

What type of equity award did the Lexeo Therapeutics (LXEO) CEO receive?

The CEO received a grant of 67,000 shares of common stock at a price of $0.00 per share. The filing also notes he holds 252,130 RSUs, each giving a contingent right to one common share, consistent with standard performance and service-based equity compensation structures.